Who are Botulinum toxin type A injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Botulinum Toxin Type A 900kD, Botulinum Toxin-A injection, Radiesse, Xeomin, Belotero, AboBoNT-A, Botox infiltration, BOTULINUM TOXIN TYPE B.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/botulinum-toxin-type-a-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Botulinum toxin type A injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Botulinum toxin type A injection (Botulinum toxin type A injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neurotoxin; botulinum toxin preparation. Area: Neurology; Aesthetics; Dermatology.

marketed Neurotoxin; botulinum toxin preparation SNAP-25 (synaptosome-associated protein of 25 kDa) Neurology; Aesthetics; Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Botulinum toxin type A injection (Botulinum toxin type A injection) — Hugel. Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Botulinum toxin type A injection TARGET	Botulinum toxin type A injection	Hugel	marketed	Neurotoxin; botulinum toxin preparation	SNAP-25 (synaptosome-associated protein of 25 kDa)
Botulinum Toxin Type A 900kD	Botulinum Toxin Type A 900kD	Allergan	marketed	Neurotoxin; acetylcholine release inhibitor	SNAP-25 (synaptosome-associated protein of 25 kDa)
Botulinum Toxin-A injection	Botulinum Toxin-A injection	Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust	marketed	Neurotoxin; neuromuscular blocking agent	SNARE complex (specifically cleaves SNAP-25)
Radiesse, Xeomin, Belotero	Radiesse, Xeomin, Belotero	Main Line Center for Laser Surgery	marketed	Dermal fillers and neurotoxin
AboBoNT-A	AboBoNT-A	Ipsen	marketed	Botulinum neurotoxin type A	SNAP-25 (synaptosome-associated protein of 25 kDa)
Botox infiltration	Botox infiltration	University Rovira i Virgili	marketed	Neurotoxin; botulinum toxin type A	SNARE complex (synaptosome-associated protein); acetylcholine release machinery
BOTULINUM TOXIN TYPE B	BOTULINUM TOXIN TYPE B	Eisai Co., Ltd.	marketed	Neurotoxin; botulinum toxin	Synaptobrevin (VAMP)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neurotoxin; botulinum toxin preparation class)

Hugel · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Botulinum toxin type A injection — Competitive Intelligence Brief. https://druglandscape.com/ci/botulinum-toxin-type-a-injection. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing